Mechanistic Target of Rapamycin Complex 1
"Mechanistic Target of Rapamycin Complex 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An evolutionarily conserved multiprotein complex that functions as a cellular energy sensor and regulator of protein synthesis for cell growth and proliferation. It consists of TOR SERINE-THREONINE KINASES; REGULATORY-ASSOCIATED PROTEIN OF MTOR (RAPTOR); MLST8 PROTEIN; and AKT1 substrate 1 protein. The activity of the complex is regulated by SIROLIMUS; INSULIN; GROWTH FACTORS; PHOSPHATIDIC ACIDS; some amino acids or amino acid derivatives, and OXIDATIVE STRESS.
| Descriptor ID |
D000076222
|
| MeSH Number(s) |
D05.500.337 D08.811.913.696.620.682.700.931.500 D12.776.476.925.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 1".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 1".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 1" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 10 | 10 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 9 | 9 |
| 2014 | 0 | 10 | 10 |
| 2015 | 0 | 9 | 9 |
| 2016 | 0 | 12 | 12 |
| 2017 | 4 | 13 | 17 |
| 2018 | 8 | 5 | 13 |
| 2019 | 1 | 5 | 6 |
| 2020 | 5 | 7 | 12 |
| 2021 | 5 | 5 | 10 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 9 | 10 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 1" by people in Profiles.
-
Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine. Am J Physiol Gastrointest Liver Physiol. 2024 May 01; 326(5):G504-G524.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex. Nat Commun. 2024 Jan 09; 15(1):406.
-
Pulsatile Leucine Administration during Continuous Enteral Feeding Enhances Skeletal Muscle Mechanistic Target of Rapamycin Complex 1 Signaling and Protein Synthesis in a Preterm Piglet Model. J Nutr. 2024 02; 154(2):505-515.
-
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 12 15; 83(24):4161-4178.
-
Targeted suppression of mTORC2 reduces seizures across models of epilepsy. Nat Commun. 2023 11 14; 14(1):7364.
-
Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature. 2023 Jul; 619(7970):616-623.
-
RagD auto-activating mutations impair MiT/TFE activity in kidney tubulopathy and cardiomyopathy syndrome. Nat Commun. 2023 05 15; 14(1):2775.
-
Review: Nutritional regulation of muscle growth in neonatal swine. Animal. 2023 Jul; 17 Suppl 3:100831.
-
CDK5-PRMT1-WDR24 signaling cascade promotes mTORC1 signaling and tumor growth. Cell Rep. 2023 04 25; 42(4):112316.